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With improved survival rates among cancer patients, fertility preservation is now being recognized as an issue of great importance.
There are currently several methods of fertility preservation available in female cancer patients and the options and techniques
via assisted reproduction and cryopreservation are increasing, but some are still experimental and continues to be evaluated. The
established means of preserving fertility include embryo cryopreservation, gonadal shielding during radiation therapy, ovarian
transposition, conservative gynecologic surgery such as radical trachelectomy, donor embryos/oocytes, gestational surrogacy, and
adoption. The experimental methods include oocyte cryopreservation, ovarian cryopreservation and transplantation, in vitro
maturation, and ovarian suppression. With advances in methods for the preservation of fertility, providing information about risk
of infertility and possible options of fertility preservation to all young patients with cancer, and discussing future fertility with
them should be also considered as one of the important parts of consultation at the time of cancer diagnosis.
1.Introduction
As a result of a remarkable improvement in the survival
rates of cancer patients, there has been an increased interest
in the long-term eﬀects of cancer treatment on quality of
life. In particular, infertility is one of the major sequelae of
caner therapy and may be considerable distress to cancer
survivors. In female patients, risk of menopause-related
complicationandinfertilityataveryyoungageduetocancer
treatment may be more devastating and be considered as a
loss of their essential femininity [1]. Even in patients who
were not sterilized after chemotherapy or radiation therapy,
increased risks of complications during pregnancy, such as
early pregnancy loss, premature labor, and low birth weight,
have been reported [2].
Although infertile patients after cancer treatment can
become parents with adoption or embryo or oocyte dona-
tion, many would prefer to have biological oﬀspring [3],
thus the demands from such patients and the creation of
various options and techniques for fertility preservation
by reproductive specialists are increasing. Several national
organizations in USA have recently published fertility-
preservation guidelines: the President’s Cancer Panel (2004),
the American Society of Reproductive Medicine Ethics
Committee (2005), and the American Society of Clinical
Oncology (2006) [4]. Some methods such as embryo cry-
opreservation,ovariantranspositionareconsideredstandard
practice but some other methods should be considered
investigational. Choosing the most appropriate ones among
these methods depends on the individual’s status such as the
type of cancer, the variations of cancer treatment, the time
available before onset of treatment, the patient’s age, and the
partner status.
This paper describes the risks for infertility, current and
emerging options for the fertility preservation in female2 ISRN Obstetrics and Gynecology
cancer, patients and the clinical/ethical issues with respect to
fertility.
2. Effects of Cancer Treatment on
Female Fertility
The most common cancers diagnosed in people under the
age of 40 are breast cancer, melanoma, cervical cancer,
non-Hodgkin’s lymphoma, and leukemia [5]. The treatment
for these malignancies implies either surgery, radiotherapy,
chemotherapy, or a combination, and they can compromise
the function of reproductive system.
In the treatment of gynecologic malignancies, the stan-
dard treatment includes surgical removal of uterus and
ovary, which eliminates the possibility of childbearing [6].
Multiple chemotherapeutic agents for many cancers result in
irreversible gonadal damage, which is related to the decline
of numbers of primordial follicles as well as a reduction
in the numbers of larger maturing follicles [7–9]. The end
result of chemotherapy-induced damage is often premature
ovarian failure leading to permanent infertility. The risk of
ovarian damage caused by the diﬀerent chemotherapeutic
agents is shown in Table 1. Alkylating agents (particularly
cyclophosphamide, ifosfamide, nitrosaureas, chlorambucil,
melphalan, busulfan, and procarbazine) are associated with
thegreatestriskofinfertilitywhileseveralagents(methotrex-
ate, ﬂuorouracil, vincristine, bleomycin, and dactinomycin)
are associated with a low or no risk of infertility [4, 10].
Radiation also causes a reduction in the primordial fol-
licle pool, and the degree of ovarian damage is dependent
o nd o s ea n dﬁ e l d[ 11, 12]. Total-body irradiation and pelvic
irradiation that includes the ovaries can highly produce
permanent ovarian failure, while lesser dose or limited
radiation ﬁelds not related to ovarian location have less
gonadal toxicity [13, 14]. The uterine volume is also aﬀected
by irradiation and decreases by 40%. Even if these patients
become pregnant, they present with restricted blood ﬂow
and impaired uterine growth thus have higher risk of
pregnancy complications including early abortion, preterm
labor, and low birth weight [15]. Cranial radiation greater
than 35 to 40Gy can impair the hypothalamic pituitary
function and cause hypogonadism [16].
The eﬀects of cancer treatment on subsequent ovarian
function vary and depend on many factors—drug, dose,
size/location of radiation ﬁeld, method of administration,
disease, age, and pretreatment fertility of the patients [4].
Therefore, when estimating the risk of infertility in female
cancer patients, the consideration of these factors should
be essential. For example, older women have higher risk of
ovarian failure after chemotherapy compared with younger
patients because of the reduced primordial follicle pool with
aging. Patients who resume thier ovarian function following
chemotherapy or radiotherapy should be recommended not
to delay childbearing for long times, but should be advised
not to become pregnant before 6–12 months after treatment
because of the toxicity of cancer treatment on oocytes
[17].
Table 1: Risks of gonadotoxicity in diﬀerent chemotherapeutic
agents.
High risk
Cyclophosphamide, ifosfamide,
nitrosoureas, busulfan, chlorambucil,
melphalan, procarbazine
Intermediate risk Cisplatin, adriamycin
Low or no risk Methotrexate, ﬂuorouracil, vincristine
bleomycin, dactinomycin
Unknown risk
Taxanes, oxaliplatin, irinotecan,
monoclonal antibodies, tyrosine kinase
inhibitors
3. Options for Fertility Preservationin
Female Cancer Patients
3.1. Established Methods of Fertility Preservation (Table 2)
3.1.1. Embryo Cryopreservation. Embryo cryopreservation
is the most established option for preserving fertility and
is widely used with well-deﬁned success rates [4]. This
method is performed with the course of in vitro fertilization
procedure involving ovarian stimulation, oocyte retrieval,
fertilization. Therefore, it requires 10–14 days from menses
for follicular development and necessitate a delay of the
chemotherapy initiation. Male partner or sperm donor for
embryo creations is also needed. One of the concerns of this
treatment is the high serum estrogen concentration during
ovarian stimulation in patients with hormone-sensitive
tumors such as breast cancer [6, 18]. The use of tamoxifen
or letrozole—SERM (selective estrogen receptor modulator)
or aromatase inhibitor—for ovarian stimulation to reduce
the risk of estrogen exposure revealed no increase of cancer
recurrenceratesinsomestudies[19,20],butlargerandlong-
term follow-up results are needed.
3.1.2. Ovarian Transposition/Radiation Shielding of Gonads.
Ovarian transposition (oophoropexy) is a surgical procedure
that places the ovaries outside of radiation ﬁeld to protect
them from irradiation. The overall success rate to retain
menstrual function and fertility is not much better than
about 50% due to scattered radiation and altered blood ﬂow
[4]. The success of this procedures depends on the extent of
radiation scatter, vascular damage, the age of patients, total
radiation dose and whether or not the ovaries are shielded
[12, 21]. There is no strong rationale of this procedure when
concurrent gonadotoxic chemotherapy is performed with
radiation [22].
Radiation shielding of gonads is also a standard method
for fertility preservation. Use of shielding during radiother-
apy is to reduce scatter radiation to the reproductive organ.
3.1.3. Conservative Gynecologic Surgery. Although the tradi-
tional and ultimate treatment of gynecologic malignancies
includes surgical removal of, or radiation to uterus and
ovary, new approaches have been developed in gynecologicISRN Obstetrics and Gynecology 3
Table 2: The established methods for fertility preservation.
Option Embryo cryopreservation Ovarian transposition/
radiation shielding gonad, Radical trachelectomy
Donor embryos/donor
oocytes/gestational
surrogacy/adoption
Pubertal status After puberty Before or after puberty After puberty After puberty
Time requirement 10–14 days from
mens/outpatient procedure
In conjunction with
radiotherapy/outpatient
procedure
In patient surgical
procedure
Varies: in conjunction with
IVF
Success rates Approximately 20–33% per
transfer
Approximately 50% due to
altered blood ﬂow and
scattered radiation
No evidence of higher
cancer Recurrence
rates
Embryo: unknown/oocytes:
40–50%/ surrogacy: 30%
oncologic surgery, focused on the preservation of key repro-
ductive organs. Radical trachelectomy, a surgical removal
of the cervix with preservation of the uterus, is a typical
established one of the conservative surgery for the fertility
preservation [23]. This operation should be restricted to
early-stage IA2-IB disease with less than 2cm in diameter
and less than 10mm invasion [24]. Rates of recurrence are
comparable to those treated by means of radical hysterec-
tomy [25]. Spontaneous pregnancies were described up to
70%, although there is increased risk of second trimester
pregnancy loss, preterm delivery, and need of the use of
assisted reproduction technologies [26, 27]. Table 3 shows
current indication and deﬁnition of conservative surgery in
other gynecologic malignancies [10].
3.1.4. Embryo/Oocyte Donation and Adoption. Although
infertile patients after cancer treatment can become parents
with embryo/oocyte donation, they would not become
biologic mothers. Therefore, one of the ways of the future
in oocyte donation may be a donation protocol using
enucleated donor oocytes.
3.2. The Experimental Methods for Fertility Preservation
(Table 4). The Panel of ASCO (American Society of Clinical
Oncology, 2006) recommended that the eﬀorts to preserve
fertility using experimental methods should be attempted
under institutional-review-board- (IRB-) approved proto-
cols [4].
3.2.1. Oocyte Cryopreservation. Cryopreservation of oocytes
can be considered as good alternative methods particularly
for single women who do not have a partner or sperm
donor.However,unfertilizedmatureoocytesaremorefragile
and are easily damaged during the freezing or thawing
process, compared with the embryo [28]. However, with
recent improvement in freeze-thaw protocols such as vit-
riﬁcation, promising results, more than 60% of mature
oocytes surviving after thawing and subsequent fertilization
r a t e sc o m p a r a b l ew i t hf r e s ho o c y t e s ,w e r er e p o r t e d[ 29, 30].
Like with embryo preservation, this option needs ovarian
stimulation and harvesting, thus concerns regarding time
delay in cancer therapy and risk of exposure to high
hormonal level can be raised.
3.2.2. Cryopreservation and Transplantation of Ovarian Tis-
sue. Ovarian tissue cryopreservation requires neither a
sperm donor nor ovarian stimulation thus can be the only
feasibleoptionforprepubertalgirlsandbeperformedimme-
diately after cancer diagnosis. Ovarian tissue is removed
via laparoscopy or laparotomy and frozen. After cancer
treatment, the ovarian tissue is thawed and reimplanted.
Cryopreservation of the primordial follicles in cortical tissue
using slow programmed freezing has better results, with up
to 65% of survival of follicles, thus is the current widely used
protocol for this method [31]. Thawed ovarian tissue can
be reimplanted orthotopically or heterotopically, and about
20 cases of autotransplantation of cryopreserved ovarian
tissue with 7 live births after orthotopic transplantation have
been reported [32–36]. The one concern proposed in the
reimplantation of ovarian tissue is the retransmission of
malignant cells, although there were no reports of cancer
recurrence after ovarian transplantation in the previous
reports. Thus the detection of cancer cells in ovarian tissue
should be performed to minimize this risk [4, 37].
3.2.3. In Vitro Maturation. In vitro maturation of immature
oocytes and fertilization has been tried in some center. Since
it does not require standard ovarian stimulation, this can
be a useful procedure for female cancer patients who need
prompt cancer therapy. Despite the development of culture
system permitting accelerated maturation and development
of primordial and primary follicles, implantation and preg-
nancy rates are generally lower than for IVF with mature
oocytes [38, 39]. Further advance of culture protocol is
needed.
3.2.4. Ovarian Suppression. Ovarian suppression induced
by gonadotropin-releasing hormone (GnRH) analogs was
expected to oﬀer ovarian protection during chemotherapy,
but this method has still insuﬃcient evidence. Although
animal studies have shown the protective eﬀectfromgonadal
damage during chemotherapy [40] and some studies in
humans have also suggested a protecive eﬀect of GnRH
agonists, these studies are criticized for some methodologic
limitations such as retrospective nature, lack of random-
ization, short duration of follow-up, use of heterogeneous4 ISRN Obstetrics and Gynecology
Table 3: Conservative surgery in gynecologic malignancies.
Indication Type of surgery Deﬁnition
Cervical cancer stage 1A2-1B1 Radical vaginal trachelectomy Laparoscopic pelvic lymphadenectomy,
resection of cervix and parametrium
Borderline ovarian tumors FIGO stage I Unilateral oophorectomy Removal of the aﬀected ovary
Ovarian epithelial cancer stage I, grade 1 Unilateral oophorectomy Removal of the aﬀected ovary
Malignant ovarian germ-cell tumor/sex
cord-stromal tumors Unilateral oophorectomy Removal of the aﬀected ovary
Epithelial adenocarcinoma grade 1, stage 1A Hormonal treatment with progestational
agents for 6 months [12]
Follow-up wit endometrial biopsies every
3m o n t h s
Table 4: The experimental methods for fertility preservation.
Option Oocytes cryopreservation
Ovarian tissue
cryopreservation and
transplantation
In vitro maturation Ovarian suppression
Pubertal status After puberty Before or after puberty After puberty After puberty
Time requirement 10–14 days from men
/outpatient procedure
Outpatient surgical
procedure
2–10 days, outpatient
surgical procedure
In conjunction with
chemotherapy
Success rates Approximately 21.6% per
transfer Case reports of 7 live births Up to 30% per embryo
transfer Conﬂicting results reported
patient groups, and chemotherapy regimen [41–43]. There-
fore, the results of large prospective, randomized clinical
studies would be needed for deﬁning the eﬀectiveness of this
option.
4.Clinicaland EthicalIssues
In clinical practice physician needs to discuss with cancer
patients about infertility as a potential risk of cancer therapy
and inform the methods of fertility preservation or refer to
reproductive specialist, but many patients have no chance
to discuss about the fertility [44]. This seems to be resulted
from oncologists’ lack of knowledge about fertility preserva-
tion methods, prioritizing discussion about life-threatening
complications, concern about potential treatment delay, and
overestimation of ﬁnancial cost [45]. Additionally, some
ethical issues—the choice of option for fertility preservation
among established and experimental methods, consenting
problem of patients under the age of 18, delaying of
cancer therapy, and disposition of embryos, oocytes, ovarian
tissue—can be faced and remained as questions when pro-
viding information and practicing of fertility preservation
[45].
5. Conclusion
With the development of conservative gynecologic surgery
and advanced technologies in assisted reproduction and
cryopreservation, the options of fertility preservation in
female cancer patients are developing and various methods
became applicable in many cases. Radical trachelectomy
can be performed for early-stage cervical cancer patients.
Embyro cryopreservation can be suggested to women with
a partner. Oocyte cryopreservation can be useful for young
females without partner. Cryopreservation of ovarian tissue
is the only option for prepubertal cancer patients and a
feasible method for all patients from diﬀerent age groups.
These options should be selected individually considering
each patient’s status such as age, partner status, medical
condition, and other situations. Above all things, discussion
with patients about the options for fertility preservation at
the time of cancer diagnosis would be the most important
task in current circumstances that the practice has not
become routine, distinguishing between established and
experimental interventions.
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